Natriuretic Peptide Receptor (NPR)

AP 811 is a selective antagonist of the natriuretic peptide clearance receptor (NPR3) with a binding affinity (Ki) of 0.48 nM. It demonstrates over 20,000-fold selectivity for NPR3 compared to NPR1. AP 811 effectively inhibits atrial natriuretic peptide (ANP)-induced stimulation of transport pumps, making it a valuable tool for research into cardiovascular and kidney function regulation.

A 71915 is a potent and competitive antagonist of the natriuretic peptide receptor A (NPRA), exhibiting a pKi value of 9.18. It effectively displaces [125I]ANP in a dose-dependent manner, with a dissociation constant (Ki) of 0.65 nM. In cellular assays, A 71915 demonstrates a significant inhibition of rat ANP-induced cGMP production in NB-OK-1 cells, making it a valuable tool for research into cardiovascular signaling pathways and related therapeutic applications.

JS11 is a selective inhibitor of natriuretic polypeptide receptor 1 (Npr1), exhibiting an IC50 of 1.9 μM for human Npr1. This compound has demonstrated the ability to alleviate pruritus in mouse models, making it a valuable tool for investigating the role of Npr1 in pruritic conditions. Its pharmacological activity positions JS11 as a significant reagent for research in dermatology and other fields related to itch sensation and regulation.

ANP [Des18-22] 4-23 amide (rat) is a polypeptide fragment derived from rat atrial natriuretic peptide (ANP) that selectively interacts with the natriuretic peptide receptor C (NPR-C). This compound is instrumental in studying NPR-C signaling pathways and evaluating the physiological effects of natriuretic peptides in cardiovascular research and related fields. Its specificity for NPR-C makes it a valuable tool for in vitro experiments aimed at elucidating receptor-mediated responses.

NPRA agonist-11 is a selective agonist of the natriuretic peptide receptor A (NPRA/NPR1), exhibiting AC50 values of 1.681 μM in humans and 0.989 μM in monkeys. This compound is integral to studies of cardiovascular diseases and may also be applicable in the exploration of related disorders. Its mechanism of action makes it a valuable tool for researchers investigating NPRA signaling pathways and their implications in physiological and pathological contexts.

Ularitide, also known as Urodilatin, is a potent vasodilator that functions through the activation of renal receptors. This natriuretic peptide plays a critical role in the regulation of renal dopamine metabolism, contributing to its cardiovascular effects. Ularitide is widely used in research related to heart failure, providing insights into renal function and fluid balance in the context of cardiovascular health.

Nesiritide acetate is a recombinant human B-type natriuretic peptide that acts as an agonist of natriuretic peptide receptors (NPRs), exhibiting Kd values of 7.3 pM and 13 pM for NPR-A and NPR-C, respectively. This compound regulates the activation and inactivation of L-type calcium channels, demonstrating significant vasodilatory, diuretic, and natriuretic actions. It is primarily utilized in the research of cardiovascular conditions, particularly heart failure and vascular remodeling following arterial injury.

Atriopeptin III (rat), a 24-amino acid atrial peptide, serves as a potent vasodilator and natriuretic agent. This compound enhances renal function while effectively reducing blood pressure, particularly demonstrated in ureter-obstructed rat kidney models. Atriopeptin III (rat) is valuable for research related to chronic renal failure and its associated mechanisms.

Ethiazide is a thiazide diuretic that functions by inhibiting renal reabsorption of sodium and water, leading to increased urine output. This compound is effective in reducing fluid retention, lowering blood volume, and consequently decreasing blood pressure. Ethiazide serves as a valuable tool in cardiovascular research, aiding investigations related to fluid balance and hypertension management.